HomeInsightsShare Holding

Alembic Pharmaceuticals Ltd Share Holding Pattern

Alembic Pharmaceuticals Ltd Share Holding Pattern

stocks purchased

₹ 1.2 Cr

Volume transacted

stocks purchased

10.3 K

stocks traded

Last Updated time: 19 Sep 9.00 AM

Promoters Holdings Over Time

Key Highlights

  • Mutual funds increased their stake in the company by 0.23% from March 2024 to June 2024.
  • FIIs/FPIs decreased their stake in the company by 0.14% from March 2024 to June 2024.

Latest Shareholding

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Alembic Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
19 Sep 20241146.5
18 Sep 20241188.75
17 Sep 20241200.4
16 Sep 20241182.3
13 Sep 20241208.55
12 Sep 20241216.4
11 Sep 20241248.6
10 Sep 20241243.25
09 Sep 20241204.15
06 Sep 20241107.65

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharmaceuticals appoints Head - Technical Operations (Sterile & Oncology)

Alembic Pharmaceuticals has appointed Sudhakar Pandiyan as Head - Technical Operations (St...

Read more

16 Sep 202417:45

News

Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

05 Sep 202413:21

News

Alembic Pharma gains after receiving USFDA nod for Betamethasone Valerate Foam

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

26 Aug 202409:55

News

Alembic Pharmaceuticals receives USFDA approval for Betamethasone Valerate Foam

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

24 Aug 202414:03

News

Alembic Pharma gets USFDA nod for Betamethasone Valerate Foam

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

24 Aug 202416:59

News

Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

13 Aug 202412:15

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

Feb 2023

Transcript

Nov 2022

Transcript

Aug 2022

Transcript

May 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

May 2021

Transcript

FAQs for EPS of Alembic Pharmaceuticals Ltd

On what factors does the shareholding pattern of Alembic Pharmaceuticals Ltd change frequently?

The shareholding pattern of Alembic Pharmaceuticals Ltd can change due to various factors such as stock market transactions, new share issuances, buy-backs, or changes in ownership by institutional and retail investors.

How often is Alembic Pharmaceuticals Ltd's shareholding pattern updated?

The Alembic Pharmaceuticals Ltd shareholding pattern is typically updated quarterly or semi-annually, depending on regulatory requirements and internal reporting schedules.

What categories are included in the shareholding pattern of Alembic Pharmaceuticals Ltd?

Categories included in the shareholding pattern of Alembic Pharmaceuticals Ltd include promoter/management holdings, institutional investors, retail investors, and others such as foreign investors.

Why is the shareholding pattern of Alembic Pharmaceuticals Ltd important for investors?

The shareholding pattern of Alembic Pharmaceuticals Ltd is important for investors as it provides insights into ownership distribution, control dynamics, and the potential influence of major shareholders on company decisions and stock performance.

Where can I find the latest shareholding pattern of Alembic Pharmaceuticals Ltd?

The latest shareholding pattern of Alembic Pharmaceuticals Ltd can be found on BlinkX. You may also check the quarterly financial reports, which are available on the company’s official website under the Investor Relations section. Additionally, you can check stock exchange websites like NSE and BSE for the most recent filings.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*